Pomegranate juice protects macrophages from triglyceride accumulation: Inhibitory effect on DGAT1 activity and on triglyceride biosynthesis

Annals of Nutrition and Metabolism

Volumn 58, Issue 1, 2011, Pages 1-9

  Rosenblat, Mira ^a   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Diacylglycerol acyltransferase 1; Macrophages; Paraoxonase 2; Pomegranate juice; Punicalagin; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 2; DIACYLGLYCEROL ACYLTRANSFERASE 1; HERBACEOUS AGENT; MESSENGER RNA; POMEGRANATE EXTRACT; PUNICALAGIN; TANNIN DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIPOGENESIS; MACROPHAGE; MALE; MICROSOME; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; POMEGRANATE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BEVERAGES; CELL LINE; DIACYLGLYCEROL O-ACYLTRANSFERASE; HYDROLYZABLE TANNINS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PUNICACEAE; TRIGLYCERIDES;

LYTHRACEAE; MUS;

EID: 78650882960     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323096     Document Type: Article

References (47)

1. Carmena R, Duriez P, Fruchart JC: Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109:III2-III7. (Pubitemid 38786436)
2. Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86: 943-949.
3. Aviram M, Rosenblat M: Paraoxonases 1, 2 and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Chem 2004; 37: 1304-1316. (Pubitemid 39349234)
4. Tiwari RL, Singh Y, Barthwal MK: Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008; 28: 483-544. (Pubitemid 351842141)
5. Lusis AJ: Atherosclerosis. Nature 2000: 404: 233-241.
6. Lundberg B: Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis 1985; 56: 93-110. (Pubitemid 15049652)
7. Lang PD, Insull W Jr: Lipid droplets in atherosclerotic fatty streaks of human aorta. J Clin Invest 1970; 49: 1479-1488.
8. Mattsson L, Johansson H, Ottosson M, Bondjers G, Wilklund O: Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. J Clin Invest 1993; 92: 1759-1765. (Pubitemid 23304540)
9. Aronis A, Madar Z, Tirosh O: Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005; 38: 1221-1230. (Pubitemid 40445539)
10. Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA: Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48: 4581-4589.
11. Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M, Amir R: Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem 2007; 55: 9559-9570. (Pubitemid 350205310)
12. Basu A, Penugonda K: Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009; 67: 49-56.
13. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B: Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71: 1062-1076. (Pubitemid 30230552)
14. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T: Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23: 423-433. (Pubitemid 38811681)
15. Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger M, Bell M, McGuire DK, Provost JC, Liker H, Aviram M: Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009; 104: 936-942.
16. Rosenblat M, Hayek T, Aviram M: Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006; 187: 363-371. (Pubitemid 43963016)
17. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M: Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008; 56: 8704-8713.
18. Fuhrman B, Volkova N, Aviram M: Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients. Nutrition 2010; 26: 359-366.
19. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M: Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001; 131: 2082-2089. (Pubitemid 32720634)
20. Aviram M, Volkova N, Coleman R, Dreher M, Reddy MK, Ferreira D, Rosenblat M: Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein E-deficient (E0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008; 56: 1148-1157. (Pubitemid 351300295)
21. Fuhrman B, Volkova N, Aviram M: Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem 2005; 16: 570-576. (Pubitemid 41188038)
22. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247. (Pubitemid 43109838)
23. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cellmediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 76: 44444-44449.
24. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M: Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 468-474. (Pubitemid 36337224)
25. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST: Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 2006; 281: 29491-29500. (Pubitemid 44536957)
26. Rosenblat M, Coleman R, Reddy ST, Aviram M: Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1. J Lipid Res 2009; 50: 870-879.
27. Meilin E, Aviram M, Hayek T: Paraoxonase 2 (PON2) decreases high glucose-induced macrophage triglycerides (TG) accumulation, via inhibition of NADPH-oxidase and DGAT1 activity: studies in PON2-deficient mice. Atherosclerosis 2010; 208: 390-395.
28. Shiner M, Fuhrman B, Aviram M: Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis 2007; 195: 313-321. (Pubitemid 350087961)
29. Rosenblat M, Volkova N, Aviram M: Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis 2010; 212: 86-92.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
31. Napolitano M, Avella M, Botham KM, Bravo E: Chylomicrons remnant induction of lipid accumulation in J774A.1 macrophages is associated with up-regulation of triacylglycerol synthesis which is not dependent on oxidation of the particles. Biochim Biophys Acta 2003; 1631: 255-264. (Pubitemid 36369361)
32. Vaziri ND, Kim CH, Phan D, Kim S, Liang K: Up-regulation of hepatic acylCoA: diacylglycerol acyltransferase-1 (DGAT1) expression in nephrotic syndrome. Kidney Int 2004; 66: 262-267. (Pubitemid 38870101)
33. Chandak PG, Radovic B, Aflaki E, Kolb D, Buchebner M, Fröhlich E, Magnes C, Sinner F, Haemmerle G, Zechner R, Tabas I, Levak-Frank S, Kratky D: Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase. J Biol Chem 2010; 285: 20192-20201.
34. Farese RV Jr, Cases S, Smith SJ: Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase. Curr Opin Lipidol 2000; 11: 229-234. (Pubitemid 30336019)
35. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Nivak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV Jr: Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998; 95: 13018-13023. (Pubitemid 28509516)
36. Maor I, Kaplan M, Hayek T, Vaya J, Hoffman A, Aviram M: Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from apolipoprotein E-deficient mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commun 2000; 269: 775-780. (Pubitemid 30440376)
37. Moore EH, Napolitano M, Prosperi A, Avella M, Suckling KE, Bravo E, Botham KM: Incorporation of lycopene into chylomicron remnant-like particles enhances their induction of lipid accumulation in macrophages. Biochem Biophys Res Commun 2003; 312: 1216-1219. (Pubitemid 37490946)
38. Lehner R, Kusis A: Biosynthesis of triacylglycerol. Prog Lipid Res 1996; 35: 169-201.
39. Coleman RA, Lee DP: Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 2004; 43: 134-176. (Pubitemid 37492937)
40. Yu YH, Zhang Y, Olelkers P, Stephen L, Sturley ST, Rader DJ, Ginsberg HN: Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. J Biol Chem 2002; 277: 50876-50884. (Pubitemid 36042254)
41. Casaschi A, Maiyoh GK, Adeli K, Theriault AG: Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulinresistant hyperlipidemic hamsters. Metabolism 2005; 54: 403-409. (Pubitemid 40250103)
42. Casaschi A, Wang Q, Dang K, Richards A, Theriault A: Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids 2002; 37: 647-652.
43. Casaschi A, Rubio BK, Maiyoh GK, Theriault AG: Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: potential role in the regulation of apolipoprotein B secretion. Atherosclerosis 2004; 176: 247-253. (Pubitemid 39369513)
44. Cerdá B, Llorach R, Cerón JJ, Espín JC, Tomás-Barberán FA: Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 2003; 42: 18-28. (Pubitemid 36286302)
45. Aronis A, Madar Z, Tirosh O: Lipotoxic effects of triacylglycerols in J774.2 macrophages. Nutrition 2008; 24: 167-176.
46. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D: Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 h. J Nutr 2006; 136: 2481-2485. (Pubitemid 44521600)
47. Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D: Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 2010; 58: 2180-2187.